ESR1 and breast cancer: Patients with oestrogen receptor (ER)-positive breast cancer have better prognosis than those with ER-negative disease, based on both a more indolent natural history but perhaps more importantly due to effective anti-oestrogen, also designated ‘endocrine,' therapy10.